|Mr. Lars Fruergaard Jorgensen||President, CEO & Member of Management Board||4.72M||N/A||1966|
|Mr. Karsten Munk Knudsen||Executive VP, CFO & Member of the Management Board||1.87M||N/A||1971|
|Mr. Henrik Ehlers Wulff||Executive VP of Product Supply, Quality & IT and Member of the Management Board||1.88M||N/A||1970|
|Ms. Camilla Sylvest||Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board||1.84M||N/A||1972|
|Dr. Martin Holst Lange||Executive VP of Development & Member of the Management Board||1.78M||N/A||1970|
|Dr. Marcus Schindler Ph.D.||EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board||1.78M||N/A||1966|
|Mr. Maziar Mike Doustdar||Executive VP of International Operations & Member of the Management Board||N/A||N/A||1970|
|Mr. Douglas J. Langa||Executive VP of North America Operations & Member of Management Board||N/A||N/A||1966|
|Mr. Ludovic Helfgott||Executive VP, Head of Rare Disease & Member of Management Board||N/A||N/A||1974|
|Ms. Tania Sabroe||Executive VP of Global People & Organisation and Member of Management Board||N/A||N/A||N/A|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S’s ISS Governance QualityScore as of December 1, 2023 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 1.